Metoprolol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Metoprolol: From Hypertension to Malignant Renovascular Hypertension
One-Sentence Summary
Metoprolol is a beta-1 selective blocker (beta-blocker) that is already marketed in South Africa as Lopresor tablets, and it is used as an antihypertensive. The TxGNN model predicts it may be effective for malignant renovascular hypertension, but there are currently 0 clinical trials and 2 publications, neither of which studies metoprolol for this condition. The prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (the SAHPRA registration record supplied has no indication text) |
| Predicted New Indication | Malignant renovascular hypertension |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on known pharmacology, metoprolol is a beta-1 selective blocker. Beta-1 blockade lowers renin release from the kidney and reduces cardiac output, so a link to renin-driven hypertension is plausible.
Renovascular hypertension is driven largely by activation of the renin-angiotensin system when the kidney is under-perfused. The malignant form is a severe, rapidly progressive variant. Because metoprolol already lowers blood pressure and renin activity, the model’s prediction is biologically reasonable.
This is a mechanistic argument only. No trial or on-topic publication supports metoprolol in this condition. Malignant hypertension is also a much more acute and severe state than routine hypertension, so efficacy in ordinary hypertension cannot simply be assumed to carry over.
Clinical Trial Evidence
Currently no related clinical trials registered. No SANCTR or PACTR entries were identified.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15231398 | 2004 | Review/Commentary | Survey of Ophthalmology | Case of a 26-year-old woman with hypertensive optic neuropathy caused by renal artery stenosis from Takayasu’s arteritis. Metoprolol is not studied. |
| 1988765 | 1991 | Cohort | Medicine | Chromogranin A as a diagnostic marker for pheochromocytoma in the differential diagnosis of hypertension. Metoprolol is not studied. |
Both papers are only loosely related to the topic. They concern the causes and diagnosis of secondary hypertension, not treatment with metoprolol.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| H/5.2/72 | Lopresor | Tablet (oral) | Not stated in the available record |
The Evidence Pack does not include Essential Medicines List (EML) status for metoprolol, so it is not reported here.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is model-only (L5), with no clinical trials and no on-topic literature. The mechanism is plausible but unverified. The SAHPRA package insert warnings and contraindications have not been reviewed, so the safety screening cannot proceed.
Other high-scoring predictions for metoprolol do not change this assessment:
- Post-myocardial-infarction subtypes are already covered by its established use, so they are not true repurposing.
- Pulmonary hypertension and chronic pulmonary heart disease carry a caution. The metoprolol COPD trial (BLOCK-COPD, NCT02587351) was terminated for futility and showed a harm signal for severe exacerbations.
To proceed, the following is needed:
- The SAHPRA package insert (Professional Information) for Lopresor, to obtain warnings, contraindications and the approved indication text. This is the blocking item.
- Mechanism of action data from DrugBank.
- Searches for disease-specific evidence in malignant and renovascular hypertension, including trials and case series.
- Clinical review of whether an oral beta-blocker has a role in an acute hypertensive emergency and in renal artery stenosis.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.